How does a bold idea become a billion-dollar biotech deal? At the 2025 Breakthrough Bootcamp during the Jefferies Global Healthcare Conference in London, Cooley partners Russell Anderson and Rama Padmanabhan sat down with EsoBiotec founder and CEO Jean-Pierre Latere to explore the promise of CAR-T therapies – and the hurdles of delivering treatments at scale.

Discover how EsoBiotec achieved rapid progress and how pivotal – and often deeply personal – moments paved the way for its transformative partnership with AstraZeneca.

About Breakthrough Bootcamp

Breakthrough Bootcamp is an interactive series of panel discussions featuring cutting-edge insights and analysis by top business leaders, investors and legal minds in the life sciences and healthcare industry. Other topics from this session included:

  • More Than Good Science: What It Takes to Be a Successful Biotech in Today’s Financing Environment – A candid conversation with seasoned biotech leaders sharing boardroom insights and fundraising strategies that go beyond the breakthrough science.
  • Co-Dev Drama and How to Be a Co-Co Pro – Lessons from real-world co-development and co-commercialization deals.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.